CA2382293A1 - Chemically-stabilized chlorite solutions for treating cancer and other diseases - Google Patents

Chemically-stabilized chlorite solutions for treating cancer and other diseases Download PDF

Info

Publication number
CA2382293A1
CA2382293A1 CA002382293A CA2382293A CA2382293A1 CA 2382293 A1 CA2382293 A1 CA 2382293A1 CA 002382293 A CA002382293 A CA 002382293A CA 2382293 A CA2382293 A CA 2382293A CA 2382293 A1 CA2382293 A1 CA 2382293A1
Authority
CA
Canada
Prior art keywords
cancer
carcinoma
cells
stabilized chlorite
macrophages
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002382293A
Other languages
English (en)
French (fr)
Inventor
Frederich W. Kuhne
Vitam Kodelja
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxo Chemie AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2382293A1 publication Critical patent/CA2382293A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/40—Peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
CA002382293A 1999-08-18 2000-08-18 Chemically-stabilized chlorite solutions for treating cancer and other diseases Abandoned CA2382293A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14942999P 1999-08-18 1999-08-18
US60/149,429 1999-08-18
PCT/US2000/022610 WO2001012205A2 (en) 1999-08-18 2000-08-18 Chemically-stabilized chlorite solutions for treating cancer

Publications (1)

Publication Number Publication Date
CA2382293A1 true CA2382293A1 (en) 2001-02-22

Family

ID=22530238

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002382293A Abandoned CA2382293A1 (en) 1999-08-18 2000-08-18 Chemically-stabilized chlorite solutions for treating cancer and other diseases

Country Status (14)

Country Link
EP (1) EP1408994A2 (zh)
KR (1) KR20020038728A (zh)
CN (1) CN1378456A (zh)
AU (1) AU6913200A (zh)
CA (1) CA2382293A1 (zh)
IL (1) IL148189A0 (zh)
MX (1) MXPA02001724A (zh)
NO (1) NO20020751L (zh)
NZ (1) NZ517673A (zh)
PL (1) PL353769A1 (zh)
RU (1) RU2002106824A (zh)
TR (1) TR200201182T2 (zh)
WO (1) WO2001012205A2 (zh)
ZA (1) ZA200201726B (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1687238B1 (de) 2003-11-21 2009-12-09 CytoTools AG Reaktive chlorverbindungen, deren derivate, anionen und salze sowie verfahren zu deren herstellung und verwendung
ES2384267T3 (es) * 2005-07-21 2012-07-03 Nuvo Research Ag Soluciones de clorito estabilizadas en combinación con fluoropirimidinas para el tratamiento del cáncer
WO2013093891A1 (en) 2011-12-22 2013-06-27 Nuvo Research Gmbh Liposomal chlorite or chlorate compositions
CN112386606A (zh) * 2019-08-19 2021-02-23 卢序 一种有第二信使作用增加积极氧化压力的氧化剂的用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3515749A1 (de) * 1985-05-02 1986-11-06 Oxo Chemie GmbH, 6900 Heidelberg Verwendung einer stabilisierten chloritmatrixloesung bei infektioesen zustaenden
DE3515748A1 (de) * 1985-05-02 1986-11-06 Oxo Chemie GmbH, 6900 Heidelberg Verwendung einer isotonen chloritmatrix-loesung bei der behandlung von tumoren
DK1021196T3 (da) * 1997-10-06 2004-06-07 Oxo Chemie Ag Anvendelse af en kemisk stabiliseret chloritoplösning til inhibering af en antigenspecifik immunreaktion
WO2000048940A1 (de) * 1999-02-19 2000-08-24 Stahl Kurt Wilhelm Peroxochlorsäure, derivate und anionen, salze davon, und verfahren zu deren herstellung und verwendung

Also Published As

Publication number Publication date
TR200201182T2 (tr) 2002-08-21
WO2001012205A3 (en) 2001-09-13
RU2002106824A (ru) 2003-11-27
NZ517673A (en) 2004-03-26
EP1408994A2 (en) 2004-04-21
ZA200201726B (en) 2003-12-31
NO20020751D0 (no) 2002-02-15
AU6913200A (en) 2001-03-13
WO2001012205A2 (en) 2001-02-22
PL353769A1 (en) 2003-12-01
KR20020038728A (ko) 2002-05-23
IL148189A0 (en) 2002-09-12
NO20020751L (no) 2002-04-17
MXPA02001724A (es) 2004-09-06
CN1378456A (zh) 2002-11-06

Similar Documents

Publication Publication Date Title
US20110076344A1 (en) Use of a chemically-stabilized chlorite solution for inhibiting an antigen-specific immune response
Brunda et al. In vivo anti‐tumor activity of combinations of interferon alpha and interleukin‐2 in a murine model. Correlation of efficacy with the induction of cytotoxic cells resembling natural killer cells
Bhardwaj et al. Interferon-gamma-activated human monocytes inhibit the intracellular multiplication of Legionella pneumophila.
Owen-Schaub et al. Synergy of tumor necrosis factor and interleukin 2 in the activation of human cytotoxic lymphocytes: effect of tumor necrosis factor α and interleukin 2 in the generation of human lymphokine-activated killer cell cytotoxicity
Wang et al. Interleukin‐10 induces macrophage apoptosis and expression of CD16 (FcγRIII) whose engagement blocks the cell death programme and facilitates differentiation
Myers et al. Interleukin‐12 gene therapy prevents establishment of SCC VII squamous cell carcinomas, inhibits tumor growth, and elicits long‐term antitumor immunity in syngeneic C3H mice
Aiura et al. Interaction with Autologous Platelets Multiplies Interleukin-l and Tumor Necrosis Factor Production in Mononuclear Cells
AU712197B2 (en) Cancer therapy using lymphotoxin
CA2382293A1 (en) Chemically-stabilized chlorite solutions for treating cancer and other diseases
Richards et al. Phase I study of weekly 24-hour infusions of recombinant human interleukin-2
Del Rosario et al. Prevention of graft-versus-host disease by induction of immune tolerance with ultraviolet B-irradiated leukocytes in H-2 disparate bone marrow donor
Krahenbuhl et al. Effects of Corynebacterium parvum treatment and Toxoplasma gondii infection on macrophage-mediated cytostasis of tumour target cells.
US20020090358A1 (en) Chronic lymphocytic leukemia treatment
Malone et al. Combination interferon-α2a and 13-cis-retinoic acid enhances radiosensitization of human malignant glioma cells in vitro
Bernsen et al. Interleukin-2: hope in cases of cisplatin-resistant tumours
Kaido et al. Host CD4+ T lymphocytes are required for the synergistic action of interferon-α/β and adoptively transferred immune cells in the inhibition of visceral ESb metastases
Beaman et al. The timing of exposure of mononuclear phagocytes to recombinant interferon γ and recombinant tumor necrosis factor α alters interactions with Nocardia asteroides
Mahaley Jr et al. New therapeutic approaches to treatment of malignant gliomas: chemotherapy and immunotherapy
Oberbeck et al. Metoclopramide and cellular immune functions during polymicrobial sepsis
Rosenfeld et al. Ex vivo purging of allogeneic marrow with L-leucyl-L-leucine methyl ester: a phase I study
Baron et al. Failure of donor lymphocyte infusion to prevent graft rejection in dogs given DLA-identical marrow after 1 Gy of total body irradiation
Teng Chronic effects of tumor necrosis factor
Neta et al. Interdependence of the radioprotective effects of human recombinant interleukin 1. cap alpha., tumor-necrosis factor. cap alpha., granulocyte colony-stimulating factor, and murine recombinant granulocyte-macrophage colony-stimulating factor
Factor Synergy of Tumor Necrosis Factor and Interleukin 2 in the
WO2004024171A1 (en) Chronic lymphocytic leukemia combination treatment (treated cll cells and cytokine)

Legal Events

Date Code Title Description
FZDE Discontinued